产品: | 磷酸化 DAG1 (Tyr892) 抗体 |
货号: | AF8216 |
描述: | Rabbit polyclonal antibody to Phospho-DAG1 (Tyr892) |
应用: | WB IHC |
反应: | Human, Mouse, Rat |
预测: | Pig, Zebrafish, Bovine, Horse, Sheep, Rabbit, Dog, Chicken, Xenopus |
分子量: | 98KD; 97kD(Calculated). |
蛋白号: | Q14118 |
RRID: | AB_2840278 |
产品描述
*The optimal dilutions should be determined by the end user.
*Tips:
WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.
引用格式: Affinity Biosciences Cat# AF8216, RRID:AB_2840278.
展开/折叠
156DAG; A3a; Agrin receptor; AGRNR; Alpha-DG; alpha-DG-N; Beta-DG; Beta-dystroglycan; DAG; Dag1; DAG1_HUMAN; Dystroglycan 1 (dystrophin-associated glycoprotein 1); Dystroglycan; Dystroglycan, alpha; Dystrophin-associated glycoprotein 1; MDDGC7; MDDGC9; OTTHUMP00000210857; OTTHUMP00000210858;
抗原和靶标
Expressed in a variety of fetal and adult tissues. In epidermal tissue, located to the basement membrane. Also expressed in keratinocytes and fibroblasts.
- Q14118 DAG1_HUMAN:
- Protein BLAST With
- NCBI/
- ExPASy/
- Uniprot
MRMSVGLSLLLPLSGRTFLLLLSVVMAQSHWPSEPSEAVRDWENQLEASMHSVLSDLHEAVPTVVGIPDGTAVVGRSFRVTIPTDLIASSGDIIKVSAAGKEALPSWLHWDSQSHTLEGLPLDTDKGVHYISVSATRLGANGSHIPQTSSVFSIEVYPEDHSELQSVRTASPDPGEVVSSACAADEPVTVLTVILDADLTKMTPKQRIDLLHRMRSFSEVELHNMKLVPVVNNRLFDMSAFMAGPGNAKKVVENGALLSWKLGCSLNQNSVPDIHGVEAPAREGAMSAQLGYPVVGWHIANKKPPLPKRVRRQIHATPTPVTAIGPPTTAIQEPPSRIVPTPTSPAIAPPTETMAPPVRDPVPGKPTVTIRTRGAIIQTPTLGPIQPTRVSEAGTTVPGQIRPTMTIPGYVEPTAVATPPTTTTKKPRVSTPKPATPSTDSTTTTTRRPTKKPRTPRPVPRVTTKVSITRLETASPPTRIRTTTSGVPRGGEPNQRPELKNHIDRVDAWVGTYFEVKIPSDTFYDHEDTTTDKLKLTLKLREQQLVGEKSWVQFNSNSQLMYGLPDSSHVGKHEYFMHATDKGGLSAVDAFEIHVHRRPQGDRAPARFKAKFVGDPALVLNDIHKKIALVKKLAFAFGDRNCSTITLQNITRGSIVVEWTNNTLPLEPCPKEQIAGLSRRIAEDDGKPRPAFSNALEPDFKATSITVTGSGSCRHLQFIPVVPPRRVPSEAPPTEVPDRDPEKSSEDDVYLHTVIPAVVVAAILLIAGIIAMICYRKKRKGKLTLEDQATFIKKGVPIIFADELDDSKPPPSSSMPLILQEEKAPLPPPEYPNQSVPETTPLNQDTMGEYTPLRDEDPNAPPYQPPPPFTAPMEGKGSRPKNMTPYRSPPPYVPP
种属预测
score>80的预测可信度较高,可尝试用于WB检测。*预测模型主要基于免疫原序列比对,结果仅作参考,不作为质保凭据。
High(score>80) Medium(80>score>50) Low(score<50) No confidence
翻译修饰 - Q14118 作为底物
Site | PTM Type | Enzyme | Source |
---|---|---|---|
T63 | O-Glycosylation | Uniprot | |
Y130 | Phosphorylation | Uniprot | |
S216 | Phosphorylation | Uniprot | |
S218 | Phosphorylation | Uniprot | |
K226 | Ubiquitination | Uniprot | |
T317 | O-Glycosylation | Uniprot | |
T317 | Phosphorylation | Uniprot | |
T319 | O-Glycosylation | Uniprot | |
T319 | Phosphorylation | Uniprot | |
T367 | O-Glycosylation | Uniprot | |
T369 | O-Glycosylation | Uniprot | |
T372 | O-Glycosylation | Uniprot | |
T379 | O-Glycosylation | Uniprot | |
T381 | O-Glycosylation | Uniprot | |
T388 | O-Glycosylation | Uniprot | |
T414 | Phosphorylation | Uniprot | |
S430 | O-Glycosylation | Uniprot | |
T431 | O-Glycosylation | Uniprot | |
K433 | Ubiquitination | Uniprot | |
T436 | O-Glycosylation | Uniprot | |
S438 | O-Glycosylation | Uniprot | |
T439 | O-Glycosylation | Uniprot | |
S441 | O-Glycosylation | Uniprot | |
T442 | O-Glycosylation | Uniprot | |
T443 | O-Glycosylation | Uniprot | |
T444 | O-Glycosylation | Uniprot | |
T445 | O-Glycosylation | Uniprot | |
T446 | O-Glycosylation | Uniprot | |
T450 | O-Glycosylation | Uniprot | |
T455 | O-Glycosylation | Uniprot | |
T463 | O-Glycosylation | Uniprot | |
T464 | O-Glycosylation | Uniprot | |
S467 | Phosphorylation | Uniprot | |
T469 | O-Glycosylation | Uniprot | |
T469 | Phosphorylation | Uniprot | |
T473 | O-Glycosylation | Uniprot | |
T473 | Phosphorylation | Uniprot | |
S475 | O-Glycosylation | Uniprot | |
S475 | Phosphorylation | Uniprot | |
T478 | O-Glycosylation | Uniprot | |
T478 | Phosphorylation | Uniprot | |
T482 | O-Glycosylation | Uniprot | |
T483 | O-Glycosylation | Uniprot | |
T484 | O-Glycosylation | Uniprot | |
S485 | O-Glycosylation | Uniprot | |
S485 | Phosphorylation | Uniprot | |
S520 | Phosphorylation | Uniprot | |
K533 | Ubiquitination | Uniprot | |
Y575 | Phosphorylation | Uniprot | |
K611 | Ubiquitination | Uniprot | |
K625 | Ubiquitination | Uniprot | |
K626 | Methylation | Uniprot | |
K687 | Ubiquitination | Uniprot | |
S729 | O-Glycosylation | Uniprot | |
T734 | O-Glycosylation | Uniprot | |
K780 | Ubiquitination | Uniprot | |
K782 | Ubiquitination | Uniprot | |
T784 | Phosphorylation | Uniprot | |
T790 | Phosphorylation | Uniprot | |
K793 | Ubiquitination | Uniprot | |
K794 | Ubiquitination | Uniprot | |
S807 | Phosphorylation | Uniprot | |
K808 | Ubiquitination | Uniprot | |
S812 | Phosphorylation | Uniprot | |
S814 | Phosphorylation | Uniprot | |
Y863 | Phosphorylation | Uniprot | |
K881 | Ubiquitination | Uniprot | |
T884 | Phosphorylation | Uniprot | |
Y886 | Phosphorylation | Uniprot | |
S888 | Phosphorylation | Uniprot | |
Y892 | Phosphorylation | P12931 (SRC) | Uniprot |
研究背景
The dystroglycan complex is involved in a number of processes including laminin and basement membrane assembly, sarcolemmal stability, cell survival, peripheral nerve myelination, nodal structure, cell migration, and epithelial polarization.
Alpha-dystroglycan is an extracellular peripheral glycoprotein that acts as a receptor for both extracellular matrix proteins containing laminin-G domains. Receptor for laminin-2 (LAMA2) and agrin in peripheral nerve Schwann cells.
Beta-dystroglycan is a transmembrane protein that plays important roles in connecting the extracellular matrix to the cytoskeleton. Acts as a cell adhesion receptor in both muscle and non-muscle tissues. Receptor for both DMD and UTRN and, through these interactions, scaffolds axin to the cytoskeleton. Also functions in cell adhesion-mediated signaling and implicated in cell polarity.
(Microbial infection) Alpha-dystroglycan acts as a receptor for lassa virus and lymphocytic choriomeningitis virus glycoprotein and class C new-world arenaviruses. Alpha-dystroglycan acts as a Schwann cell receptor for Mycobacterium leprae, the causative organism of leprosy, but only in the presence of the G-domain of LAMA2.
O-glycosylated. POMGNT1 catalyzes the initial addition of N-acetylglucosamine, giving rise to the GlcNAc(beta1-2)Man(alpha1-)O-Ser/Thr moiety and thus providing the necessary basis for the addition of further carbohydrate moieties. Alpha-dystroglycan is heavily O-glycosylated comprising of up to two thirds of its mass and the carbohydrate composition differs depending on tissue type. Mucin-type O-glycosylation is important for ligand binding activity. O-mannosylation of alpha-DAG1 is found in high abundance in both brain and muscle where the most abundant glycan is Sia-alpha-2-3-Gal-beta-1-4-Glc-NAc-beta-1-2-Man. In muscle, glycosylation on Thr-317, Thr-319 and Thr-379 by a phosphorylated O-mannosyl glycan with the structure 2-(N-acetylamido)-2-deoxygalactosyl-beta-1,3-2-(N-acetylamido)-2-deoxyglucosyl-beta-1,4-6-phosphomannose is mediated by like-acetylglucosaminyltransferase (LARGE1) protein and is required for laminin binding. O-mannosylation is also required for binding lymphocytic choriomeningitis virus, Old World Lassa fever virus, and clade C New World arenaviruses. The O-glycosyl hexose on Thr-367, Thr-369, Thr-372, Thr-381 and Thr-388 is probably mannose. O-glycosylated in the N-terminal region with a core 1 or possibly core 8 glycan.
The beta subunit is N-glycosylated.
Autolytic cleavage produces the alpha and beta subunits. In cutaneous cells, as well as in certain pathological conditions, shedding of beta-dystroglcan can occur releasing a peptide of about 30 kDa.
SRC-mediated phosphorylation of the PPXY motif of the beta subunit recruits SH2 domain-containing proteins, but inhibits binding to WWW domain-containing proteins, DMD and UTRN. This phosphorylation also inhibits nuclear entry.
Secreted>Extracellular space.
Cell membrane>Single-pass type I membrane protein. Cytoplasm>Cytoskeleton. Nucleus>Nucleoplasm. Cell membrane>Sarcolemma. Cell junction>Synapse>Postsynaptic cell membrane.
Note: The monomeric form translocates to the nucleus via the action of importins and depends on RAN. Nuclear transport is inhibited by Tyr-892 phosphorylation. In skeletal muscle, this phosphorylated form locates to a vesicular internal membrane compartment. In muscle cells, sarcolemma localization requires the presence of ANK2, while localization to costameres requires the presence of ANK3. Localizes to neuromuscular junctions (NMJs) in the presence of ANK2 (By similarity). In peripheral nerves, localizes to the Schwann cell membrane. Colocalizes with ERM proteins in Schwann-cell microvilli.
Expressed in a variety of fetal and adult tissues. In epidermal tissue, located to the basement membrane. Also expressed in keratinocytes and fibroblasts.
Monomer. Heterodimer of alpha- and beta-dystroglycan subunits which are the central components of the dystrophin-glycoprotein complex. This complex then can form a dystrophin-associated glycoprotein complex (DGC) which is composed of three subcomplexes: a cytoplasmic complex comprised of DMD (or UTRN), DTNA and a number of syntrophins, such as SNTB1, SNTB2, SNTG1 and SNTG2, the transmembrane dystroglycan complex, and the sarcoglycan-sarcospan complex. Interacts (via the N-terminal of alphaDAG1) with LARGE1; the interaction enhances laminin binding (By similarity). Interacts with SGCD. Interacts with AGR2 and AGR3. Interacts (betaDAG1) with DMD; the interaction is inhibited by phosphorylation on the PPXY motif. Interacts (betaDAG1, via its PPXY motif) with UTRN (via its WWW and ZZ domains); the interaction is inhibited by phosphorylation on the PPXY motif. Interacts (betaDAG1, via its phosphorylated PPXY motif) with the SH2 domain-containing proteins, FYN, CSK, NCK and SHC. Interacts (betaDAG1) with CAV3 (via a central WW-like domain); the interaction disrupts the binding of DMD. BetaDAG1 directly interacts with ANK3, but not with ANK2; this interaction does not interfere with DMD-binding and is required for retention at costameres (By similarity). Identified in a dystroglycan complex that contains at least PRX, DRP2, UTRN, DMD and DAG1 (By similarity). Interacts with POMGNT1.
(Microbial infection) Interacts with lassa virus and lymphocytic choriomeningitis virus glycoprotein.
(Microbial infection) Interacts with surface molecules of mycobacterium leprae.
研究领域
· Environmental Information Processing > Signaling molecules and interaction > ECM-receptor interaction. (View pathway)
· Human Diseases > Cardiovascular diseases > Hypertrophic cardiomyopathy (HCM).
· Human Diseases > Cardiovascular diseases > Arrhythmogenic right ventricular cardiomyopathy (ARVC).
· Human Diseases > Cardiovascular diseases > Dilated cardiomyopathy (DCM).
· Human Diseases > Cardiovascular diseases > Viral myocarditis.
限制条款
产品的规格、报价、验证数据请以官网为准,官网链接:www.affbiotech.com | www.affbiotech.cn(简体中文)| www.affbiotech.jp(日本語)产品的数据信息为Affinity所有,未经授权不得收集Affinity官网数据或资料用于商业用途,对抄袭产品数据的行为我们将保留诉诸法律的权利。
产品相关数据会因产品批次、产品检测情况随时调整,如您已订购该产品,请以订购时随货说明书为准,否则请以官网内容为准,官网内容有改动时恕不另行通知。
Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时,请您在Affinity官方渠道提交售后申请。产品仅供科学研究使用。不用于诊断和治疗。
产品未经授权不得转售。
Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.